Discussion: Whilst in most cases the mutations would be unlikely to significantly compromise a second-line regimen based on a ritonavir-boosted
PI, five patients had complex mutation patterns (three or more TAMs or
Q151M complex) that might substantially limit the future activity of the
NRTI class of drugs.